Titlebook: ;

Malinger

書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC影響因子(影響力)




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC影響因子(影響力)學(xué)科排名




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC網(wǎng)絡(luò)公開度




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC被引頻次




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC被引頻次學(xué)科排名




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC年度引用




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC年度引用學(xué)科排名




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC讀者反饋




書目名稱Guide to Targeted Therapies: EGFR mutations in NSCLC讀者反饋學(xué)科排名

匍匐前進(jìn)

FISC

Ancillary

獨(dú)輪車

啞巴

啞巴

旋轉(zhuǎn)一周

慢慢沖刷

The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function,r 1 [HER1]), HER2 (c-ErbB-2), HER3 (c-ErbB-3), and HER4 (c-ErbB-4). These proteins are coded by distinct genes that are expressed on chromosomes 7, 17, 12, and 2, respectively. Although specific soluble ligands have been identified for the extracellular domains of EGFR, HER3, and HER4, no ligand has been identified for HER2.

胡言亂語

Conclusions,. In patients with non-small cell lung cancer (NSCLC) it is now mandatory to evaluate . (.) mutation status before treatment choice and EGFR tyrosine kinase inhibitors (TKIs) are the optimal option in the patients harboring activating . mutations.